Home >
Colombian Group of Psoriasis and Psoriatic Arthritis (ColPsor)
2012/10/26 - News from medical groups
Introduction
The Colombian Group of Psoriasis and Psoriatic Arthritis (ColPsor) is a non-profit study group gathering dermatologists and rheumatologists interested in promoting psoriasis knowledge and in improving the quality of life of patients suffering from these pathologies.
ColPsor is endorsed by the Colombian Association of Dermatology and Dermatologic Surgery (Asocolderma), it is a part of the Latin American Society of Psoriasis (Solapso) and it support de Colombian Foundation of Patients with Psoriasis (Fundapso).
Goal
Tha main interest of ColPsor is to encourage dermatologists, rheumatologists, internists, patients and the scientific community as a whole to generate together information on the behavior of the disease in our environment and thus promote an interdisciplinary and participative debate on topics favoring the comprehensive management of psoriasis.
ColPsor is composed of opinion leaders in psoriasis from all over Colombia and it is open to new members and to doctors who share ColPsor’s academic interests.
Academic endorsements
ColPsor is part of the Solapso and its delegates to the organization are members of the executive committee of the ColPsor. Solapso fully supports the academic activities of ColPsor, which is the reason why only ColPsor is authorised to organise the Solapso’s regional activities in Colombia.
Fundapso has solicited technical and scientific advice from ColPsor’s members in order to provide support and therapeutic education to psoriatic patients. As a result, dermatologists and rheumatologists from ColPsor are members of Fundapso’s scientific committee.
Activities
During the last 2 years, ColPsor has organized scientific events, supported by Asocolderma, destined to share advances in the understanding of psoriasis with dermatology and rheumatology residents, internists, and dermatologists and rheumatologists from all over Colombia. In the same way, we have promoted and supported events for patients organized by Fundapso.
1st ColPsor meeting
- Bogotá, May 8, 2010
2nd ColPsor meeting
- Medellín, July 23, 2011
3rd ColPsor meeting
- Cali, September 24, 2011
Solapso Symposium "Advances in the understanding of psoriasis: a new perspective" at XXVIII National Dermatology and Dermatologic Surgery Congress & XVI ATD International
- Bogotá, Colombia. September 17, 2010
1st Colombian-Venezuelan Solapso Symposium at XLVII VENEZUELA CONGRESS OF DERMATOLOGY
- Valencia, Venezuela. November 10-12, 2011
2nd Colombian-Venezuelan Solapso Symposium at XXIX Dermatology and Dermatologic Surgery Congress
- Armenia, Colombia, August 4, 2012
Publications
a. Scientific Articles
- González C. Psoriasis, implicaciones laborales. Revista de la Sociedad Colombiana de Medicina del Trabajo. 2004; 7:26-30
- González C, Castro L, Gutiérrez L, Rodríguez V, Londoño J, Santos AM, Escobar A, Valle R. Comportamiento epidemiológico y clínico de la Psoriasis en la Población Colombiana. Rev Colomb Reumatol. 2005; 12: 278 - 278
- Candia L, Márquez J, González C, Santos AM, Londoño J, Valle R, Zabaleta J, Yaqub Z, Espinoza LR. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol. 2006; 12:226-9.
- Fonseca D, Castro L, González C, Aristizabal. L, Cruz C, Sánchez X et al. Inmunología y terapia biológica en psoriasis. Rev Asoc Colomb Dermatol 2007;03: 208-18
- González C, Castro L, De la Cruz G, Arenas C, Beltrán A, Santos AM. Caracterización epidemiológica de la Psoriasis en el Hospital Militar Central. Rev Asoc Colomb Dermatol 2009; 17: 11 - 17.
- Sierra C, Velásquez M. Psoriasis: revisión del tema con énfasis en la inmunopatogénesis. Iatrea. 2009;(22) No 3:272-83
- Fernández D, Beltrán A, Londoño J, Reyes E, Mora C, Santos P, Candia L, Valle R. Diagnóstico de Artritis Psoriática. Rev Colomb Reumatol.2009; 16: 342-351
- Ruiz C, González Z, Jiménez SB, Velásquez M. Diagnóstico de la tuberculosis latente en la era de la terapia biológica. Rev Asoc Colomb Dermatol. 2010;18: 139-48
- González C, Castro L, Velásquez M, Londoño A, Echeverri MA, Hernández N, et al. Ustekinumab. Rev Asoc Colomb Dermatol 2010; 17: s.1-28
- Vélez N, Bohórquez L, Corrales MF, Orrego S, Jiménez SB, Zuluaga de Cadena A, et al. Caracterización de los pacientes con psoriasis en tratamiento con fototerapia. Rev Asoc Colomb Dermatol. 2011; 19:100-6.
b. Posters
- González G, Castro L, Londoño A, Vargas M, Sánchez X. Terapia biológica en Psoriasis, Experiencia con Etanercept en Colombia, serie de casos. Póster. XXVII Congreso Nacional de Dermatología y Cirugía Dermatológica. 2008.
- González G, Castro L, Londoño A, Vargas M, Sánchez X. Terapia biológica en Psoriasis, Experiencia con Infliximab en Colombia, serie de casos. Póster. XXVII Congreso nacional de dermatología y cirugía dermatológica. 2008.
- Castro L, González C, Avellaneda C Beltrán A, Manrique G, Fernández D, et al. Ejercicio de aplicación de una encuesta de tamizaje para artritis psoriática en pacientes con psoriasis. Póster. XXVIII Congreso nacional de dermatología y cirugía dermatológica. 2010.
- Varela J, Castro L, González C, 1 Londoño J, Beltrán A, Bautista W, Valle- Oñate R. Prevalence of Psoriatic Arthritis in patients with Psoriasis. GRAPPA Annual Meeting Trainees Symposium, Miami. Dec 2010
- Castro L, González C, Amador J, Castañeda A et al. Endothelial dysfunction, cardiovascular risk factors, and metabolic syndrome in a cohort of patients with psoriasis in the "Hospital Militar Central de Colombia. Poster, GRAPPA Annual Meeting Trainees Symposium, Miami. Dec 2010
c. Books
- Chalela JG, González C, Castro L, et al. Guías Colombianas de Psoriasis. Consenso Colombiano. Editorial Nomos. 2008
- 1er Consenso Latinoamericano de Psoriasis. Rio de Janeiro, Brasil. 2009 en www.solapso.org/archivos/LATINOAMERICANO-1_2009.pdf
- González C, Londoño A, Castro L, et al. Guías basadas en la evidencia para el manejo de la psoriasis en Colombia. Editorial Panamericana. 2012
National Coordinators
Bogotá: Cesar González, Luis Castro, Adriana Beltrán
Medellín: Angela Londoño, Margarita Velásquez, Oscar Felipe
Cali: Myriam Vargas, Lucy García
Costa Atlántica: Esperanza Meléndez
Eje cafetero: Angela Seidel
Corporate Image
Colombian Group of Psoriasis and Psoriatic Arthritis, ColPsor
Symbol
Key concepts: Movement, Surmount, Optimism
This symbol is, on one hand, the abstract representation of some characteristics of psoriasis; on the other hand it communicates some concepts one wishes to relate to the ColPsor group, such as movement and optimism.
The bottom curve line represents the skin surface; the smaller elements, seeming to advance towards the top are the graphic representation of the scales that usually appear when the cells accumulate in the surface. The psoriasis is represented by the graphic elements that move towards the right.
In another way, the graphic elements that appear toward the top also represent a group, union of people wanting to progress a move forward; they transmit strength and dynamism. As such, the same characteristics of the disease make way for something positive; one should not hide the psoriasis but speak of it with clarity in order to surmount it.
Abbreviated name
Colombian Group of Psoriasis and Psoriatic Arthritis
To make it easy to recognize the group, an abbreviated form of the group’s name was created, using the first part of the most significant names of the group’s name, Colombia and psoriasis, as to create the short name of ColPsor.
Logo
Color of Corporate Image
The used colors are black, grey and orange. The color orange was chosen because it conveys vitality, life and optimism.
Contact
Cesar González: drcesargonzalez@yahoo.com.ar
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Conformational dynamics in interleukin 17A and 17F functional complexes is a key determinant of receptor A affinity and specificity.
Cytokine.
2021 Jun , 142:155476.
The proinflammatory cytokines IL-17A and IL-17F have been identified as key drivers of a range of human inflammatory diseases, such as psoriasis, which has led to several therapeutic antibodies targeted at IL-17A. The two cytokines have been shown to tightly associate as functional homo and hetero dimers, which induce signalling via the formation of a cell surface signalling complex with a single copy of both IL-17RA and IL-17RC. Striking differences in affinity have been observed for (...)
see on pubmed
Protective Effects of Polyvinylpyrrolidone-Wrapped Fullerene Against Nitric Oxide/Peroxynitrite-Induced Cellular Injury in Human Skin Keratinocytes.
J Nanosci Nanotechnol.
2021 Sep 01, 21, (9):4579-4585.
Excess ultraviolet (UV) exposure accelerates skin inflammation, melanogenesis, wrinkle formation, photoaging, and carcinogenesis through oxidative stress and deoxyribonucleic acid damage. These deleterious effects to skin are closely associated with UV-induced reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced via nitric oxide (NO) generation. RNS are known to be responsible for various skin disorders, such as erythema, melanin production, reduced barrier function, (...)
see on pubmed
Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.
Bioengineered.
2021 Dec , 12, (1):183-195.
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide population, and causing long-term troubles to the patients. Therefore, it is urgent to develop safe and effective therapeutic drugs. Catalpol is a natural iridoid glucoside, that has several remarkable pharmacological effects, however, whether catalpol can alleviated psoriasis has not been explored. The goal of the present work is to study the role of catalpol in psoriasis in vivo and in vitro. (...)
see on pubmed
on Atopic Dermatitis
Viral metagenomic identification of a novel anellovirus in blood sample of a child with atopic dermatitis.
J Med Virol.
2021 Jun , 93, (6):4038-4041.
Here, using viral metagenomics, a novel anellovirus with strain name HuAV-zj-ad1 was detected in blood sample from a child with atopic dermatitis. The complete genome sequence of HuAV-zj-ad1 was determined and fully characterized. The circular genome of HuAV-zj-ad1 is 2841 nt in length and includes four polyprotein ORFs. Phylogenetic analysis and pairwise sequence comparisons based on the amino acid sequences of ORF1, ORF2, ORF3, ORF4 indicated that HuAV-zj-ad1 belonged to a novel species (...)
see on pubmed
Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
Auris Nasus Larynx.
2021 Jun , 48, (3):353-360.
Eosinophilic otitis media (EOM) is an intractable otitis media mostly associated with bronchial asthma. Dupilumab, an anti-interleukin (IL)-4 receptor (R)α, is effective and has been approved for use in patients with moderate to severe bronchial asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis, whose diseases are not controlled by previous treatments including other molecular targeted drugs. We aimed to assess efficacy of dupilumab in three EOM patients with (...)
see on pubmed
Methicillin-resistant from infected skin lesions present several virulence genes and are associated with the CC30 in Brazilian children with atopic dermatitis.
Virulence.
2021 12 , 12, (1):260-269.
Atopic dermatitis (AD) is a chronic inflammatory skin disease and colonization by may affect up to 100% of these patients. Virulent and resistant isolates can worsen AD patient clinical condition and jeopardize the treatment. We aimed to detect virulence genes and to evaluate the biofilm production of isolates from infected skin lesions of children with AD. Methicillin resistance was detected by phenotypic and molecular tests and the virulence genes were detected by PCR. Biofilm formation (...)
see on pubmed
